Clinical characteristics, treatment and outcome of nivolumab-induced myasthenia gravis

[1]  R. Sherchan,et al.  Nivolumab, a Double-Edged Sword: A Case Report of Nivolumab-Induced Myasthenia Gravis , 2021, Journal of medical cases.

[2]  F. Zimprich,et al.  Subgroup stratification and outcome in recently diagnosed generalized myasthenia gravis , 2020, Neurology.

[3]  B. Miñón-Fernández,et al.  [Myasthenia gravis associated with nivolumab]. , 2020, Revista de neurologia.

[4]  M. Suarez‐Almazor,et al.  Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature , 2019, Journal of Immunotherapy for Cancer.

[5]  B. Guillot,et al.  Myasthenia Gravis Induced by Immune Checkpoint Inhibitors. , 2019, Journal of immunotherapy.

[6]  A. Schulze-Bonhage,et al.  Recurrent episodes of falls and amnestic confusional states as diagnostic challenge in the elderly , 2019, BMJ Case Reports.

[7]  A. Curtis,et al.  Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: Case Series and Review of the Literature , 2019, Case Reports in Oncology.

[8]  L. Gianni,et al.  PD-1 Inhibitors-Related Neurological Toxicities in Patients with Non-Small-Cell Lung Cancer: A Literature Review , 2019, Cancers.

[9]  G. Fink,et al.  Successful Treatment of Myasthenia Gravis Following PD-1/CTLA-4 Combination Checkpoint Blockade in a Patient With Metastatic Melanoma , 2019, Front. Oncol..

[10]  T. Liewluck,et al.  Neuromuscular Complications of Programmed Cell Death-1 (PD-1) Inhibitors , 2018, Current Neurology and Neuroscience Reports.

[11]  Sandra Sousa,et al.  Myasthenia Gravis Induced by Ipilimumab in a Patient With Metastatic Melanoma , 2018, Front. Neurol..

[12]  M. Suarez‐Almazor,et al.  Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Shigeaki Suzuki,et al.  Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan , 2017, Neurology.

[14]  A. Takano,et al.  Continued Response to One Dose of Nivolumab Complicated by Myasthenic Crisis and Myositis. , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[15]  M. Benatar,et al.  International consensus guidance for management of myasthenia gravis , 2016, Neurology.

[16]  Chul Kim,et al.  Nivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: Role in advanced cancers , 2016, Human vaccines & immunotherapeutics.

[17]  M. Akiyama,et al.  Nivolumab for the treatment of malignant melanoma in a patient with pre-existing myasthenia gravis , 2016, Nagoya journal of medical science.

[18]  J. Sosman,et al.  Myasthenia Gravis Induced by Ipilimumab in Patients With Metastatic Melanoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  J. Wolchok,et al.  Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  S. Tummala,et al.  Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma. , 2014, Neuro-oncology.

[21]  E. Fish,et al.  SeXX matters in immunity. , 2014, Trends in immunology.

[22]  A. Kesler,et al.  Statin-Associated Myasthenia Gravis: Report of 4 Cases and Review of the Literature , 2006, Medicine.

[23]  D B Sanders,et al.  Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. , 2000, Neurology.

[24]  H. Milner-Brown,et al.  Prednisone‐induced worsening of neuromuscular function in myasthenia gravis , 1986, Neurology.

[25]  M. Wahidi,et al.  NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY Management of Immunotherapy- Related Toxicities, Version 1.2019 , 2019 .

[26]  S. Klein,et al.  Sex-based differences in immune function and responses to vaccination. , 2015, Transactions of the Royal Society of Tropical Medicine and Hygiene.